Share this page

Seasonal malaria chemoprevention

What is SMC?

Seasonal malaria chemoprevention (SMC) is a highly effective intervention to prevent malaria in those most vulnerable to the disease's effects. It involves administering monthly doses of antimalarial drugs to children aged 3-59 months during peak malaria transmission season.

Our SMC programme in Burkina Faso, Chad and Nigeria is top rated by GiveWell for its effectiveness.In 2020 we also expanded our SMC work to Togo and will be undertaking a research study to establish if SMC can have similar results in Mozambique.

Click here to learn more

Image Breakout

We strive to continuously improve quality of SMC implementation and to contribute to the evidence base through monitoring and evaluation (M&E) and research. Find out about our work on SMC implementation in our SMC newsletter. 

SMC Timeline 

2006

Randomised clinical trials

Results from randomised clinical trials of intermittent preventive treatment in children and SMC conducted between 2006 and 2011, showed strong evidence that the use of intermittent antimalarial drug administration in areas of seasonal transmission could prevent up to 75% of severe malaria cases

2012

WHO recommends SMC

Results from randomised clinical trials of intermittent preventive treatment in children and SMC conducted between 2006 and 2011, showed strong evidence that the use of intermittent antimalarial drug administration in areas of seasonal transmission could prevent up to 75% of severe malaria cases

In March 2012, the World Health Organization (WHO) recommends SMC—a combination of sulfadoxine-pyrimethamine and amodiaquine (SPAQ)— once a month for 4 months. This coincides coincides with the peak transmission period during the rainy season, as a prevention intervention for children between 3 to 59 months in areas with high seasonal malaria transmission in the Sahel region of sub-Saharan Africa

2013

Roll out of SMC in Nigeria

With support from the Bill & Melinda Gates Foundation and the DFID-funded Support for the National Malaria Programme (SuNMaP), Malaria Consortium pilots the roll out of SMC across Katsina and Jigawa states in northern Nigeria to determine the feasibility of large-scale implementation and to conduct formative research. Over three years (2013 – 2015) during peak transmission seasons, a total of 500,000 children benefited from SMC

2014

Guilin pharmaceutical co obtains WHO prequalification

Guilin Pharmaceutical Co. in China obtains WHO prequalification for a co-blistered combination pack of SP and AQ

2015

Malaria Consortium publishes the SMC start up guide for Nigeria

Malaria Consortium publishes the SMC Start-Up Guide for Nigeria. The guide provides the Nigeria National and State Malaria Elimination Programmes, implementing partners, and stakeholders with a practical guide to planning, implementing and evaluating a sustainable programme for SMC in northern Nigeria

2015

Malaria Consortium leads major scale up in 7 countries

ACCESS-SMC is a UNITAID funded project, led by Malaria Consortium in partnership with Catholic Relief Services, which is supporting National Malaria Control Programs to scale up access to seasonal malaria chemoprevention to save children’s lives across seven countries in the Sahel.

2015

12.5 Million preventative SMC treatments distributed

ACCESS SMC’s first campaign in 2015 provides 12.5 million preventive SMC treatments to 3.2 million eligible children

2015

Access SMC estimated to have prevented 60,000 deaths

According to project data, it is estimated that ACCESS SMC may have averted over 60,000 deaths and prevented over 10 million cases of malaria

2016

Access SMC reaches 6.9 million eligible children

ACCESS SMC administers 25 million treatments reaching 6.9 million children between the ages of 3-59 months

2016

Top Charity recommended by Givewell

Malaria Consortium receives top charity status for our SMC programme by charity evaluator GiveWell

2017

Access SMC supports a further SMC season

ACCESS SMC continues to support a further SMC season in Burkina Faso, Chad, Guinea, Mali, Niger, Nigeria and The Gambia. Philanthropic funding also helped support the SMC season in Burkina Faso, Chad, Guinea-Bissau and Nigeria

2017

GiveWell top charity status continues

Malaria Consortium’s SMC programme is recommended as a GiveWell top charity for second year in a row

2018

Malaria Consortium continues supporting SMC in 3 countries

Despite the end of ACCESS SMC, Malaria Consortium continues supporting the delivery of SMC in three countries - Burkina Faso, Chad and Nigeria - thanks largely to new philanthropic funding

2018

Malaria Consortium reaches 4.1 Million Children

Thanks to our GiveWell status, we receive grants from Good Ventures, a philanthropic foundation whose mission is to help humanity thrive. We also receive other charitable donations for the SMC programme from US, UK, Europe and Australia which allowed us to reach 4.1 million children with SMC in Burkina Faso, Chad and Nigeria

2018

Malaria Consortium maintains top charity status 3rd year in a row

GiveWell announces that Malaria Consortium’s seasonal malaria chemoprevention programme is recommended as the number 1 top charity for the third year in a row

2019

UK aid and Global Fund support SMC

In 2019, delivery of SMC in Northern Nigeria is also supported by UK aid from the UK government through our SuNMaP 2 project and the Global Fund

2019

6 million children reached in 2019

In 2019, we delivered SMC to 6 million children in Burkina Faso, Chad and Nigeria

2020

SMC set to reach more than 30 million children for the first time

The number of children set to receive seasonal malaria chemoprevention in 2020 will exceed 30 million for the first time, according to the figures presented by national malaria programmes at a global planning and review meeting in Ghana in February 2020

2020

Malaria Consortium to pilot seasonal malaria chemoprevention outside Sahel for first time

Malaria Consortium is drawing on its expertise in designing and implementing cutting edge research to establish if seasonal malaria chemoprevention can have similar results in countries like Mozambique.The study will be implemented in partnership with Mozambique’s National Malaria Control Programme (NMCP) and Centro de Investigação em Saúde de Manhiça.

2020

Malaria Consortium maintains top charity status 5th year in a row

GiveWell announces that Malaria Consortium’s seasonal malaria chemoprevention programme is recommended as the number 1 top charity for the fifth year in a row